-
-
-
-
-
-
-
Biogen and Denali discontinue Parkinson's drug after trial fails
-
-
-
-
-
-
-
UBS upgrades Biogen, sees up to 50% upside on pipeline catalysts
-
-
-
-
-
-
-
Biogen forecasts upbeat annual profit, eyes 2028 launch of key drugs
-
-
-
-
-
-
-
Stifel lifts Biogen to Buy, sees potential Alzheimer's narrative shift
-
-
-
-
-
-
-
Biogen signals Leqembi sales gaining momentum, lifts profit forecast
-
-
-
-
-
-
-
Stifel Reiterates Hold Rating on Biogen (BIIB) Following EPS
-
-
-
-
-
-
-
Bernstein starts Biogen at ‘market-perform,’ notes near term uncertainty
-
1,216,180 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

